GlaxoSmithKline
葛兰素史克
elsewhere's corpus does not cover GlaxoSmithKline as a subject in its own right. The only material that names the company is a November 2025 BlueRun Ventures announcement about its partnership with Ze'an Biopharmaceutical (LTZ Therapeutics), in which GSK appears as the counterparty to a $50 million upfront drug-development deal focused on LTZ's myeloid cell engager platform for oncology . No entity card or dedicated chunk profiles GSK's business, history, or current operations.
AI-generated — may contain errors, please verify.
GlaxoSmithKlineCompany
葛兰素史克
渲染中…
Mentioned in 5 articles
Coverage
BlueRun Ventures Early-Stage Portfolio Company Shian Biosciences Enters Exclusive ALK7 siRNA Licensing Agreement with GSK | BlueRun Ventures Family Headlines
Attempting to tackle risk management from more fundamental pathological links.
AncorBio in the Hot ADC Race: Mining Differentiated Value in the Innovative Drug 2.0 Era | Gaorong Future
China will inevitably give rise to its own global MNCs.
In the AI Era, There Are Only Builders — No Seats on the Sidelines | Quarterly
Let's go.
$50 Million Upfront Payment! Zeon Secures Another Partnership with Global Pharma Giant | BlueRun Ventures Family Headlines
Ze'an Partners with Another Global Pharma Giant
